Clinical trials: Metastasis Colorectal Cancer
Metastatic Colorectal Cancer
Biomarker - Panitumumab Response With KRAS Wild Type MCC
This is an exploratory study in which all eligible subjects are given Panitumumab according to the dose and schedule approved by Health Canada.
- Trial name
- NCT00853931
- Testing
- Panitumumab
- Where
- 3 sites in Canada
- Volunteers
- 52 people
- Sponsor
- British Columbia Cancer Agency
Metastatic Colon Cancer
Curcumin in Combination With 5FU for Colon Cancer
The purpose of this study is to test the safety and find the response rate of combining the dietary supplement, curcumin, with the standard of care, FDA-approved chemotherapy drug 5-fluorouracil (5FU, Adracil) and see what…
- Trial name
- NCT02724202
- Testing
- Curcumin, 5-flurorouracil
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Baylor Research Institute
Colon Adenocarcinoma
COLON ERDERLY LOW DOSE
In this retrospective observational study, the case series of patients undergoing first-line treatment for metastatic colorectal adenocarcinoma with doublet fixed-dose and reduced-dose chemotherapy in combination with full-dose…
- Trial name
- CELOW (NCT06840977)
- Where
- 2 sites in Italy
- Volunteers
- 51 people
- Sponsor
- Matteo Clavarezza
Elderly Metastatic Colorectal Cancer Patients
Study of I Line FOLFOX + Panitumumab vs 5FU + Panitumumab in RAS and BRAF WT Metastatic Colorectal Cancer Elderly Patients
Few data are available about the treatment of metastatic colorectal cancer (mCRC) elderly patients with anti-EGFR agents in combination with chemotherapy.
- Trial name
- PANDA (NCT02904031)
- Testing
- 5-fluorouracil, oxaliplatin, l-leucovorin
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Recurrent Colon Cancer, Recurrent Rectal Cancer
Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer
This phase II trial is studying dasatinib to see how well it works in treating patients with previously treated metastatic colorectal cancer.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
- Trial name
- NCT00504153
- Testing
- dasatinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Metastatic Cancer
Oxaliplatin, Capecitabine, and Bevacizumab Followed By Surgery and/or Radiofrequency Ablation in Patients With Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00408772
- Testing
- bevacizumab, capecitabine, oxaliplatin
- Where
- United States
- Sponsor
- University of California, Davis
Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8
Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer
This phase Ib trial tests the safety, side effects, and effectiveness of botensilimab, and balstilimab in combination with a fasting mimicking diet and high dose vitamin C in treating patients with KRAS-mutant metastatic…
- Trial name
- NCT06336902
- Testing
- Balstilimab, Biospecimen Collection, Botensilimab
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Southern California
Metastatic Colorectal Cancer
Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC
A randomized phase II trial of FOLFOXIRI in Combination With GM-CSF and IL-2 (FOLFOXIGIL) Versus FOLFOXIRI as First-line Treatment for Patients With Metastatic Colorectal Cancer.
- Trial name
- NCT03222089
- Testing
- Irinotecan, Oxaliplatin, Levoleucovorin
- Where
- China
- Sponsor
- Fujian Cancer Hospital
Colorectal Cancer, Liver Metastasis
Liver Transplantation for Colorectal Cancer
This is an observational study that will follow adults with stage IV colorectal cancer whose disease has spread only to the liver (not to other organs) and who are undergoing a liver transplant as part of their cancer treatment.
- Trial name
- NCT07884110
- Testing
- Liver transplantation
- Where
- Chile
- Volunteers
- 10 people
- Sponsor
- Pontificia Universidad Catolica de Chile
Metastatic Colorectal Cancer
New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer
This is a single-center, single-arm study designed to evaluate the efficacy and safety of second-line treatment in patients with advanced colorectal cancer (those who have progressed on or are intolerant to first-line…
- Trial name
- NCT07559760
- Testing
- Levofolinic Acid + 5-FU continuous infusion + irinotecan HCl liposome ± cetuximab/bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Hospital of Jilin University
Colorectal Cancer
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00556413
- Testing
- cetuximab, fluorouracil, irinotecan hydrochloride
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Metastatic Colorectal Cancer (CRC)
Personalized T-Cell Therapy iNeo-Vac-T01 in Advanced Colorectal Cancer
The primary objective of this study is to evaluate the feasibility, safety, and efficacy of personalized T-cell therapy based on tumor neoantigens in patients with advanced colorectal cancer, so as to provide a novel…
- Trial name
- NCT07504523
- Testing
- iNeo-Vac-T01
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ying Yuan, MD
Colorectal Cancer Metastatic, Chemotherapy
Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer
The current phase 2, double cohort clinical trial was designed to determine the effectiveness of Trifluridine and Tipiracil Hydrochloride Tablets, Bevacizumab and Sintilimab with/without involved lesions irradiation as 3rd- or…
- Conditions
- Colorectal Cancer Metastatic, Chemotherapy, Targeted Therapy, Immunotherapy
- Trial name
- NCT06764680
- Testing
- Trifluorouracil tepidopyrimidine, Bevacizumab, Sindilizumab
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Sun Yat-sen University
Colorectal Neoplasms
Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer
To determine the safety and efficacy of AG-013736 in combination with other standard of care medication in patients with first line metastatic colorectal cancer.
- Trial name
- NCT00460603
- Testing
- bevacizumab, AG-013726, AG-013736 (axitinib)
- Where
- 106 sites in United States
- Volunteers
- 187 people
- Sponsor
- Pfizer
Colorectal Cancer, Head and Neck Cancer
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
The study is expected to identify a safe dose of BMS-754807 to be given in combination with a standard dose of cetuximab and the recommended dose or dose range for Phase II studies.
- Conditions
- Colorectal Cancer, Head and Neck Cancer, Neoplasm Metastasis
- Trial name
- NCT00908024
- Testing
- BMS-754807, cetuximab (Erbitux®)
- Where
- 5 sites in United States, Canada
- Volunteers
- 54 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Colorectal Cancer
Triplet (FOLFOXIRI) vs. Doublet (FOLFOX or FOLFIRI) Regimen as a 1st Line Treatment in Metastatic Colorectal Carcinoma
This is a prospective randomized phase II trial was done in clinical oncology department at Kasr Alainy hospital, Cairo university (NEMROCK) to evaluate the role of intensification of chemotherapy in the first line for treatment…
- Trial name
- NCT05316818
- Testing
- FOLFOXIRI Protocol
- Where
- Egypt
- Volunteers
- 64 people
- Sponsor
- Kasr El Aini Hospital
Colorectal Cancer
GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal Cancer
This is a Phase III trial. All enrolled subjects are patients with metastatic colorectal cancer (mCRC) harboring KRAS G12D mutations who have previously received systemic therapy.
- Trial name
- NCT07913360
- Testing
- GFH375 + Cetuximab, Fruquintinib, Trifluridine and Tipiracil
- Volunteers
- 368 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
Anal Cancer, Colorectal Cancer
Interleukin-12 in Treating Patients With Cancer in the Abdomen
RATIONALE: Interleukin-12 may kill tumor cells by stimulating a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-12 in treating patients with cancer in the abdomen.
- Conditions
- Anal Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer
- Trial name
- NCT00003046
- Testing
- Recombinant Interleukin-12
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Liver Metastasis Colon Cancer
Sonazoid-enhanced Ultrasound for the Detection of Colorectal Liver Metastases Less Than 2 cm
Preoperative chemotherapy is often used for patients with colorectal cancer liver metastasis (CLM). Many small CLMs (<=2cm) may disappear after chemotherapy, while most of these are still alive.
- Trial name
- NCT04686942
- Testing
- After sonazoid
- Where
- China
- Volunteers
- 550 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer
Clinical Study of Capecitabine, Oxaliplatin and Bevacizumab in Colorectal Cancer
This study will evaluate the efficacy, safety and pharmacokinetics of capecitabine (2000 mg/m2/day by mouth [po], day 1 pm-day 15 am every 3 weeks [q3w]), oxaliplatin (130 mg/m2 intravenously [iv], day 1 q3w) and bevacizumab (7.5…
- Trial name
- NCT00345761
- Testing
- Bevacizumab, Oxaliplatin, Capecitabine
- Where
- 4 sites in Japan
- Volunteers
- 64 people
- Sponsor
- Chugai Pharmaceutical
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.